STAT+: Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments
Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments.
News
STAT+: After blazing trails in RNA-targeted drugs, Ionis jumps into gene editing
Ionis Pharmaceuticals — which blazed a trail in RNA-targeted medicines — is jumping into gene editing with a new partnership with Metagenomi. […]
News
STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharma industry. […]
News
STAT+: Pharmalittle: FDA increasingly pausing trials of experimental meds; FDA commish isn’t surprised by congressional report on Alzheimer’s drug
The FDA is pressing pause on testing of experimental medicines more often, a side effect of the drug industry’s move into promising but less-proven technologies. […]
